Indications and uses
Bruises or Muscle Soreness
Bruises or Muscle Soreness
Adults: Dissolve 4 tablets under tongue 4 times a day. Children: consult a healthcare professional.
Bruises or Muscle Soreness
ARNICA MONTANA 6X
Bruises or Muscle Soreness
Made according to the Homeopathic Pharmacopoeia of the United States since 1903.
Do not use if cap band is missing or broken.
If you are pregnant or nursing, consult a licensed health care professional before using this product.
If symptoms persist for 7 days or worsen, contact a licensed practitioner.
Keep this and all medicines out of the reach of children.
To be used according to label indications and/or standard homeopathic indications.
Adults: Dissolve 4 tablets under tongue 4 times a day.
Children: consult a healthcare professional.
Acacia Gum and Lactose
800-624-9659
Bruises or Muscle Soreness
Adults: Dissolve 4 tablets under tongue 4 times a day.
Children: consult a healthcare professional.
SINCE 1903
Hyland's
®
HOMEOPATHIC
NDC 54973-0604-4
ARNICA
MONTANA
6X
BRUISES OR MUSCLE
SORENESS*
250 TABLETS
*Claims are based on traditiona
l homeopathic practice, not
accepted medical evidence.
Not FDA evaluated.
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| ACACIA | INACTIVE INGREDIENT | 5C5403N26O | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54973-0604 | 54973-0604-4 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ACACIA | 5C5403N26O | IACT |
| LACTOSE | J2B2A4N98G | IACT |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| ACACIA | ACACIA | 5C5403N26O | SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, COATED / ORAL | 156 mg | ||
| ACACIA | ACACIA | 5C5403N26O | CAPSULE / ORAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, ORALLY DISINTEGRATING / ORAL | 7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| ACACIA | ACACIA | 5C5403N26O | POWDER, FOR SUSPENSION / ORAL | 7386 mg | ||
| ACACIA | ACACIA | 5C5403N26O | SYRUP / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| ACACIA | ACACIA | 5C5403N26O | LOZENGE / ORAL | 108 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET / ORAL | 70 mg | ||
| ACACIA | ACACIA | 5C5403N26O | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| ACACIA | ACACIA | 5C5403N26O | SUSPENSION / ORAL | 2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| ACACIA | ACACIA | 5C5403N26O | GUM, CHEWING / BUCCAL | 280 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, CHEWABLE / ORAL | 121 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, FILM COATED / ORAL | 0.14 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET / SUBLINGUAL | 9.1 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| ACACIA | ACACIA | 5C5403N26O | POWDER / ORAL | 800 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| ACACIA | ACACIA | 5C5403N26O | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET / BUCCAL | 9.1 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, EXTENDED RELEASE / ORAL | 34.4 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2c4044c4-076b-c0ac-e063-6394a90ab577 | f35c6450-face-4855-b559-69aea8fb478f | 2025-01-21 | Warnings | f35c6450-face-4855-b559-69aea8fb478f |
Adverse event summaries are temporarily unavailable. Other product information remains available.